To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
Evotec Signs High Throughput Screening Collaboration with Alios Biopharma
Read time: Less than a minute
Evotec AG has announced collaboration with Alios Biopharma, Inc in the area of high throughput screening (HTS).
Alios BioPharma, Inc. is a biotechnology company that is developing novel medicines that treat diseases in virology by activating pathways in the innate immune system.
Evotec will use its proprietary ultra-HTS platform and technology to screen a priority biological target for Alios. Evotec’s HTS technology has been developed in collaboration with its pharmaceutical partners Pfizer, Novartis and GSK. It combines an ultra sensitive detection technology with a miniaturized screening format. In addition, Alios will access Evotec’s high quality small molecule screening library for the screen.
Dr. Leonid Beigelman, Executive Vice President of Research, from Alios commented: “Evotec has compiled a small molecule screening library that provides excellent diversity and high quality. This, combined with their exceptional HTS technology makes them an ideal partner for screening our important target with the aim of finding high quality hits for our subsequent medicinal chemistry efforts.”
Evotec’s EVP, Business Development, Dr Mark Ashton commented on the collaboration: “We are pleased that Alios have chosen Evotec to provide HTS support for their important target. We are excited about identifying new hits for their program and supporting them in their quest for new treatments for virology diseases.”
No financial details are disclosed.
Alios BioPharma, Inc. is a biotechnology company that is developing novel medicines that treat diseases in virology by activating pathways in the innate immune system.
Evotec will use its proprietary ultra-HTS platform and technology to screen a priority biological target for Alios. Evotec’s HTS technology has been developed in collaboration with its pharmaceutical partners Pfizer, Novartis and GSK. It combines an ultra sensitive detection technology with a miniaturized screening format. In addition, Alios will access Evotec’s high quality small molecule screening library for the screen.
Dr. Leonid Beigelman, Executive Vice President of Research, from Alios commented: “Evotec has compiled a small molecule screening library that provides excellent diversity and high quality. This, combined with their exceptional HTS technology makes them an ideal partner for screening our important target with the aim of finding high quality hits for our subsequent medicinal chemistry efforts.”
Evotec’s EVP, Business Development, Dr Mark Ashton commented on the collaboration: “We are pleased that Alios have chosen Evotec to provide HTS support for their important target. We are excited about identifying new hits for their program and supporting them in their quest for new treatments for virology diseases.”
No financial details are disclosed.
